Eric Mikula, PhD, from ViaLase sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss the company's femtosecond laser image-guided high-precision trabeculectomy, FLigHT, for non-incisional glaucoma treatment at this year's ARVO meeting.
Ram Kannan, PhD, FARVO, principal investigator and adjunct professor of Ophthalmology at David Geffen School of Medicine, UCLA, Doheny Eye Institute, made a pair of presentations at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans. He offers some of the highlights in a conversation with Ophthalmology Times.
Ophthalmology Times® talked with Carlos Ciller, PhD, the co-founder and CEO of RetinAI, about technological advances the company is making to drive innovation and to accelerate drug development pipelines at this year's ARVO meeting.
Ophthalmology Times® talked with Kaustubh Ghosh, PhD, about lysyl oxidase, a recently discovered molecule that causes the blood vessels in the eye to become stiffer at this year's ARVO meeting.
Ophthalmology Times® talked with Alfonso Sabater, MD, PhD where he discusses a patient case of his with epidermolysis bullosa at this year's ARVO meeting.
Ophthalmology Times® talked with AnnMarie Hipsley, DPT, PhD, about 3D finite element model used to understand more about the biomechanics of accommodation and dis-accommodation as it relates to functions for visual function as well as aqueous hydrodynamics at this year's ARVO meeting.
This year’s event will offer attendees both new and returning special events and features.
Ophthalmology Times® talked with Darius Moshfeghi, MD, about BUTTERFLEYE data trial results using aflibercept versus laser for the treatment of retinopathy of prematurity this year's ARVO meeting.
Ophthalmology Times® talked with Mary Durbin, PhD, about a convolutional neural network that provides image quality assessment at this year's ARVO meeting.
Ophthalmology Times® talked with Andrew Moshfeghi, MD, MBA, about OTX-TKI in a phase 1 study looking at patients with neovascular AMD this year's ARVO meeting.
Ophthalmology Times® talked Nevin El-Nimri, MS, OD, PhD, FAAO, about the relationship between optic disc fovea distance, axial length and disc at this year's ARVO meeting.
Ophthalmology Times® talked with David Tabano, PhD, from Genentech about the company's first real-world data readouts for faricimab in the treatment of DME at this year's ARVO meeting.
Ophthalmology Times® talked with Theresa Heath, MD, MBA, about Non-viral gene therapy targeting ABCA4 retinopathies at this year's ARVO meeting.
Ophthalmology Times® talked with Michael Ip, MD, about the 5 year follow-up of the original SCORE2 dataset from the NIH-sponsored clinical trial.at this year's ARVO meeting.
Ophthalmology Times® talked with David Brown, MD, about the PHOTON study examining the safety and efficacy of high-dose aflibercept for the treatment of diabetic macular edema (DME) at this year's ARVO meeting.
Ophthalmology Times® talked with Allen Chiang, MD, about the assessment of geographic atrophy progression from the Phase 3 OAKS and DERBY trials at this year's ARVO meeting.
Ophthalmology Times® talked with Kaushal Solanki, PhD, CEO and founder of Eyenuk, about EyeArt, an AI system cleared by the FDA to detect diabetic retinopathy at this year's ARVO meeting.
According to data presented at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans, composite efficacy data validate MCO-010 as a potential treatment for RP.
According to Clearside Biomedical, the suprachoroidal delivery of small molecule suspensions demonstrated targeted, compartmentalized and durable drug delivery.
Ophthalmology Times® talked with Bruce Ksander, PhD, about epigenetic reprogramming to reverse aging and restore function to retinal ganglion cells at this year's ARVO meeting.
Ophthalmology Times® talked with Steven Carrubba, MD, about monkeypox skin disease and eye disease in patients who were immunocompromised in New York at this year's ARVO meeting.
Ophthalmology Times® talked with David Tanzer, MD, about OcuTerra Therapeutics and their development of OTT166 in the treatment of diabetic retinopathy.
According to the company, consistent clinical efficacy across multiple signs and symptoms of dry eye along with excellent safety and tolerability build a differentiating product profile.
The company shared data at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans that demonstrated that a single oral dose of D-4517.2 significantly reduced choroidal neovascularization lesions to a level comparable to D-4517.2 delivered subcutaneously and aflibercept administered intravitreally at the same mass dose in a laser-induced CNV mouse model.
In a presentation at ARVO 2023 in New Orleans, Yuyu Pharma’s YP-P10 is a novel, patented, synthetic peptide with anti-inflammatory properties being explored for the potential treatment of dry eye disease.
The company shared data at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans that demonstrated OpRegen surgical bleb coverage of areas of GA may be critical for optimizing patient outcomes.
Ophthalmology Times® talked with Christine Kay, MD, about the treatment of GUCY2D associated Leber congenital amaurosis type 1 at this year's ARVO meeting.
Ophthalmology Times® talked with Penny Asbell, MD, FACS, MBA, about the ARMOR study and antibiotic resistance at this year's ARVO meeting.
.png "Optometry Times"){kind=logo}
